Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma

被引:15
作者
Maier, Gary
Rubino, Christopher
Hsu, Roger
Grasela, Thaddeus
Baumgartner, Rudolf A.
机构
[1] Sepracor Inc, Marlborough, MA 01752 USA
[2] Cognigen Corp, Buffalo, NY USA
关键词
levalbuterol; population pharmacokinetics; pediatric; asthma;
D O I
10.1016/j.pupt.2006.05.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy. Methods: The data for this analysis were collected from patients enrolled in a randomized, double-blind, multicenter, placebo- and active-controlled study evaluating the safety and efficacy of levalbuterol in asthmatic children aged 4-11 years. Patients received either levalbuterol 0.31 mg, levalbuterol 0.63 mg, racemic albuterol 1.25 mg, or racemic albuterol 2.5 mg via nebulizer. Separate population pharmacokinetic models were developed for (R)- and (S)-albuterol using the NOMNEM((R)) computer program. Covariate models were developed to identify significant predictors of inter-patient variability. Results: A total of 995 samples and 262 patients were used for the (R)-albuterol population PK model while a total of 496 samples and 128 patients were used for the (S)-albuterol population PK model. The apparent clearance of (R)-albuterol was much more rapid than that of (S)-albuterol (approximately four-fold higher), and the apparent volume of distribution was much larger for (R)-albuterol (in part due to pre-systemic metabolism) than for (S)-albuterol (approximately four-fold higher). Conclusions: In this study of pediatric patients, the models were able to demonstrate using two to four samples per patient that the apparent clearance and volume of distribution of (R)-albuterol were several fold higher than that of (S)-albuterol. The pharmacokinetics of (R)-albuterol were similar after administration of levalbuterol or racemic albuterol and were linear over the examined dose range (0.31-0.63 mg nebulized dose). The presence of (S)-albuterol did not significantly alter the pharmacokinetics of (R)-albuterol, suggesting that effects of (S)-albuterol may be due to the intrinsic pharmacology of this isomer. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:534 / 542
页数:9
相关论文
共 29 条
[1]   (S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells [J].
Agrawal, DK ;
Ariyarathna, K ;
Kelbe, PW .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (03) :503-510
[2]   Modulation of T-cell function by R- and (S)-isomers of albuterol: Anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer [J].
Baramki, D ;
Koester, J ;
Anderson, AJ ;
Borish, L .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (03) :449-454
[3]  
BEAL SL, 1998, NONMEM USERS GUIDE 2
[4]  
BEAL SL, 1995, NONMEM USERS GUIDE
[5]   The pharmacokinetics of levosalbutamol - What are the clinical implications? [J].
Boulton, DW ;
Fawcett, JP .
CLINICAL PHARMACOKINETICS, 2001, 40 (01) :23-40
[6]   SOME OBSERVATIONS ON BETA-ADRENOCEPTOR AGONIST PROPERTIES OF ISOMERS OF SALBUTAMOL [J].
BRITTAIN, RT ;
FARMER, JB ;
MARSHALL, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1973, 48 (01) :144-147
[7]   (S)-Albuterol increases the production of histamine and IL-4 in mast cells [J].
Cho, SH ;
Hartleroad, JY ;
Oh, CK .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2001, 124 (04) :478-484
[8]   REGULAR INHALED SALBUTAMOL AND AIRWAY RESPONSIVENESS TO ALLERGEN [J].
COCKCROFT, DW ;
MCPARLAND, CP ;
BRITTO, SA ;
SWYSTUN, VA ;
RUTHERFORD, BC .
LANCET, 1993, 342 (8875) :833-837
[9]   Comparison of regularly scheduled with as-needed use of albuterol in mild asthma [J].
Drazen, JM ;
Israel, E ;
Boushey, HA ;
Chinchilli, VM ;
Fahy, JV ;
Fish, JE ;
Lazarus, SC ;
Lemanske, RF ;
Martin, RJ ;
Peters, SP ;
Sorkness, C ;
Szefler, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) :841-847
[10]   Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells [J].
Eaton, EA ;
Walle, UK ;
Wilson, HM ;
Aberg, G ;
Walle, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (03) :201-206